U.S. Clinical Trials Begin for Twice-Yearly HIV Prevention Injection Studies Will Focus on Priority Populations Underrepresented in HIV Clinical Research

https://www.niaid.nih.gov/news-events/us-clinical-trials-begin-twice-yearly-hiv-prevention-injection?utm_campaign=+60856975&utm_content=&utm_medium=email&utm_source=govdelivery&utm_term= The NIAID-supported HIV Prevention Trials Network launched two clinical trials to examine lenacapavir, a novel long-acting form of HIV pre-exposure prophylaxis administered every six months, in cisgender women and people who inject drugs. The trials complement ongoing large efficacy studies and are intended to provide insights on how these two priority populations experience lenacapavir-based HIV PrEP. The studies are sponsored and funded by Gilead-Sciences.